News | May 30, 2024
Merck to acquire EyeBio for US$ 1.3 billion upfront payment
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Hepatitis B infects over 40 million people in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
